Delfa

Delfa

AI-driven PRM automating trial recruitment

Overview

Delfa provides an AI-native operating system to automate clinical trial operations, starting with patient recruitment. Its platform uses multilingual AI agents to outreach via phone, SMS, and chat to pre-screen eligibility, answer questions, schedule visits, and send reminders, while centralizing communications and data and syncing with CTMS. Delfa differentiates itself through end-to-end automation, multilingual agents, and tight CTMS integration, serving clinical research site networks with real-world case results. Its goal is to become a full-stack operating system for clinical trials that enables smarter site selection and automated study start-up to reduce enrollment delays.

About Delfa

Simplify's Rating
Why Delfa is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

11-50

Company Stage

Seed

Total Funding

$3.8M

Headquarters

London, United Kingdom

Founded

2024

Get referred to Delfa

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2025 seed round raised $3.8 million from Air Street Capital.
  • Delfa reports 50+ live trials and 300+ total supported trials by August 2026.
  • Founder Tom Farrand sold applied AI into J&J and Medtronic; buyers trust that pedigree.

What critics are saying

  • Deep 6 AI and Tempus attack the same trial-matching workflow with richer EHR data.
  • Veeva, Advarra, and CROs can bundle recruitment into broader trial systems.
  • A bad patient-contact or eligibility error triggers FDA scrutiny and kills enterprise adoption.

What makes Delfa unique

  • Delfa runs multilingual voice, SMS, and chat agents across 300+ trials.
  • Air Street-backed product writes directly into CRM and CTMS, reducing recruiter manual entry.
  • Customer stories show 36,600 patient interactions and $42,000 labor savings.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$3.8M

Above

Industry Average

Funded Over

1 Rounds

Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Above Average

Industry standards

$3.3M
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood
$3.8M
Delfa

Benefits

Health Insurance

Gym Membership

Paid Holidays

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
Upstarts Media
Aug 26th, 2025
Delfa Raises $3.8M for Voice AI Trials

London-based startup Delfa, which accelerates patient enrollment in clinical trials using voice AI, has raised $3.8 million from Air Street Capital. Delfa automates patient outreach, screening, and enrollment, saving recruiters up to 20 hours per week and speeding up trials. The funding will help build a CRM for patient recruitment. Delfa currently supports over 50 trials, mainly in the U.S., and aims to work directly with pharma companies to standardize and improve trial management.

Recently Posted Jobs

Sign up to get curated job recommendations

Delfa is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →